merck co inc

Merck board approves $5 billion in stock buybacks

Newsvine - business  Wed, 04/27/2011 - 05:58

Merck & Co. Inc. said Wednesday its board of directors approved the buyback of up to $5 billion in common stock for the drug developer's treasury.

Tags:

 

Notable 52-Week NYSE New Highs and Lows 11/19: CAH, DCI, RX, KG,...

StreetInsider.com News Articles  Thu, 11/19/2009 - 12:15

Notable 52-week Highs on the NYSE:

  • Cardinal Health, Inc. (NYSE: CAH) - Hit $31.77. UBS initiated coverage with a Buy rating on Cardinal.
  • Donaldson Company Inc.

    (NYSE: DCI) - touched $45.09. The company reported Q110 earnings about the Street estimates today.
  • IMS Health Inc.

    (NYSE: RX) - reached $21.65
  • King Pharmaceuticals Inc. (NYSE: KG) - hit $11.88. May be benefitting from mixed ZymoGenetics ratings regarding Recothrom.
  • Merck & Co.

    Inc. (NYSE: MRK) - up to $35.72. Subsidiary made milestone payment to Ligand today.
  • Trina Solar Ltd. (NYSE: TSL) - went to $45.23.

Tags:

 

After-Hours Movers 6/10: MBRX, PALM, PLXS Higher; ATPG, ATU, VMC...

StreetInsider.com News Articles  Wed, 06/10/2009 - 15:29

Metabasis Therapeutics, Inc. (Nasdaq: MBRX) 26.4% HIGHER; announced that its four year research collaboration with Merck & Co., Inc.

(NYSE: MRK), focused on the discovery and development of AMP protein kinase activators, has yielded a lead candidate that Merck has selected to advance into late preclinical development.

In addition, under an amended agreement, Merck has agreed to pay Metabasis a one-time fee of $6 million that satisfies all future obligations for milestones and royalty payments.

Tags: